Personal information

No personal information available

Activities

Collapse all

Employment (1)

Chugai Seiyaku Kabushiki Kaisha: Chuo-ku, Tokyo, JP

Employment
Source: Self-asserted source
Shun Shimizu

Works (4)

Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.

Cancer immunology research
2024-06-01 | Journal article | Author
DOI: 10.1158/2326-6066.cir-23-0638
PMID: 38558120
Contributors: Hirofumi Mikami; Shu Feng; Yutaka Matsuda; Shinya Ishii; Sotaro Naoi; Yumiko Azuma; Hiroaki Nagano; Kentaro Asanuma; Yoko Kayukawa; Toshiaki Tsunenari et al.
Source: Self-asserted source
Shun Shimizu

Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment.

Cell reports
2020-12-01 | Journal article
DOI: 10.1016/j.celrep.2020.108542
PMID: 33357423
Contributors: Futa Mimoto; Tatsumi K; Shimizu S; Kadono S; Kenta Haraya; Nagayasu M; Suzuki Y; Fujii E; Kamimura M; Hayasaka A et al.
Source: Self-asserted source
Shun Shimizu

Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective <i>In Vivo</i> without Systemic Immune Activation.

Cancer discovery
2020-08-25 | Journal article
DOI: 10.1158/2159-8290.cd-20-0328
PMID: 32847940
Contributors: Mika Kamata-Sakurai; Narita Y; Hori Y; Nemoto T; Uchikawa R; Honda M; Hironiwa N; Taniguchi K; Shida-Kawazoe M; Metsugi S et al.
Source: Self-asserted source
Shun Shimizu

Selection of mRNA 5'-untranslated region sequence with high translation efficiency through ribosome display.

Biochemical and biophysical research communications
2008-06-09 | Journal article
DOI: 10.1016/j.bbrc.2008.05.173
PMID: 18544339
Contributors: Masayasu Mie; Shimizu S; Takahashi F; Kobatake E
Source: Self-asserted source
Shun Shimizu
How many people are using ORCID?